IGF-1 DES
Also known as: Des(1-3)IGF-1 · DES IGF-1 · Truncated IGF-1 · IGF-1 Des 1-3
A truncated analog of IGF-1 missing the first 3 amino acids from the N-terminus. This modification dramatically reduces its affinity for IGF-binding proteins (IGFBPs), making it approximately 10x more potent than native IGF-1 at the receptor level, with a much shorter half-life ideal for local/acute muscle actions.
What is IGF-1 DES? A truncated analog of IGF-1 missing the first 3 amino acids from the N-terminus. This modification dramatically reduces its affinity for IGF-binding proteins (IGFBPs), making it approximately 10x more potent than native IGF-1 at the receptor level, with a much shorter half-life ideal for local/acute muscle actions.
How does IGF-1 DES work? IGF-1 DES lacks the IGFBP-binding domain found in native IGF-1, so nearly 100% of the administered dose reaches IGF-1R on target cells. This makes it extremely potent locally. When injected intramuscularly post-workout, it acts rapidly on satellite cells and muscle fibers at the injection site with minimal systemic spillover. Activates Akt/mTOR and MAPK pathways for protein synthesis.
Benefits of IGF-1 DES: ~10x more potent than native IGF-1 at receptor level; Local tissue action when injected IM (minimal systemic spillover); Rapid satellite cell activation; Intense post-workout local muscle growth stimulus; Shorter half-life for precise timing; Works synergistically with IGF-1 LR3 (DES for acute local, LR3 for systemic)
IGF-1 DES dosage: Inject directly into worked muscle groups immediately post-workout. Pair with carbohydrates. Short half-life makes timing critical. Typical dose: 50-150mcg per site.
Research status: Research Only
Source: PeptideWiki — https://www.peptide-wiki.net/peptides/igf-1-des
Mechanism of Action
IGF-1 DES lacks the IGFBP-binding domain found in native IGF-1, so nearly 100% of the administered dose reaches IGF-1R on target cells. This makes it extremely potent locally. When injected intramuscularly post-workout, it acts rapidly on satellite cells and muscle fibers at the injection site with minimal systemic spillover. Activates Akt/mTOR and MAPK pathways for protein synthesis.
Benefits
- ~10x more potent than native IGF-1 at receptor level
- Local tissue action when injected IM (minimal systemic spillover)
- Rapid satellite cell activation
- Intense post-workout local muscle growth stimulus
- Shorter half-life for precise timing
- Works synergistically with IGF-1 LR3 (DES for acute local, LR3 for systemic)
Side Effects & Risks
- Hypoglycemia risk (less than IGF-1 LR3 systemically but significant locally)
- Extreme local swelling at injection site
- Must pair with carbohydrates
- Very short half-life means poor ROI from single injection
Storage & Reconstitution Guide
Storage Temperature
-80°C long-term, -20°C short-term
24 months (lyophilized), 28 days (reconstituted)
Reconstitution Solvent
Bacteriostatic water (BAC water); use with carbohydrates
Swirl gently — do not shake or vortex
Handling Notes
Protect lyophilized peptide from moisture and light. Once reconstituted, keep refrigerated. Discard if solution becomes cloudy or discolored. Use insulin syringe for precise dosing.
Step-by-Step Reconstitution
Gather supplies
BAC water, insulin syringe, alcohol swabs, vial
Disinfect tops
Swab rubber stoppers of both vials with alcohol
Draw BAC water
Pull desired mL of BAC water into syringe
Inject slowly
Inject BAC water down the side of the peptide vial, swirl gently to dissolve
Research Protocol
- Dose Range
- 50–150 mcg
- Frequency
- Immediately post-workout, IM injection into worked muscles
- Cycle
- 2-4 weeks
- Routes
- intramuscular injection
- Notes
- Inject directly into worked muscle groups immediately post-workout. Pair with carbohydrates. Short half-life makes timing critical. Typical dose: 50-150mcg per site.
Legal & Regulatory Status
Sold for research purposes only. Not for human use. Laws vary by country.
Commonly Stacked With
View all peptide stacks →External Resources
Chemical Properties
- Mol. Weight
- ~7,400 Da
PeptideWiki Research Team
Evidence-based research data sourced from PubMed and ClinicalTrials.gov · Last updated: February 25, 2026
Frequently Asked Questions About IGF-1 DES
What is IGF-1 DES?▾
A truncated analog of IGF-1 missing the first 3 amino acids from the N-terminus. This modification dramatically reduces its affinity for IGF-binding proteins (IGFBPs), making it approximately 10x more potent than native IGF-1 at the receptor level, with a much shorter half-life ideal for local/acute muscle actions.
What are the benefits of IGF-1 DES?▾
~10x more potent than native IGF-1 at receptor level
What are the benefits of IGF-1 DES?▾
Local tissue action when injected IM (minimal systemic spillover)
What are the side effects of IGF-1 DES?▾
Hypoglycemia risk (less than IGF-1 LR3 systemically but significant locally)
What is the recommended dosage for IGF-1 DES?▾
Inject directly into worked muscle groups immediately post-workout. Pair with carbohydrates. Short half-life makes timing critical. Typical dose: 50-150mcg per site.
How long should a IGF-1 DES cycle last?▾
2-4 weeks
More Body Composition Peptides
View all Body Composition peptides →MK-677 (Ibutamoren)
Ibutamoren
A non-peptide, orally active growth hormone secretagogue that mimics ghrelin, significantly elevating GH and IGF-1 levels. Unique in being orally bioavailable.
CJC-1295 No DAC (Mod GRF 1-29)
Modified GRF 1-29
A synthetic 29-amino acid GHRH analog with 4 amino acid substitutions that improve stability and receptor affinity compared to Sermorelin. Unlike CJC-1295 DAC, it has no Drug Affinity Complex, giving it a short 30-minute half-life that mimics the body's natural pulsatile GHRH secretion when co-administered with a GHRP.
Follistatin-344
FST-344
A naturally occurring protein that inhibits myostatin and activin, effectively removing the biological ceiling on muscle growth.
MGF (Mechano Growth Factor)
Mechano Growth Factor
A splice variant of IGF-1 released in muscle fibers in response to mechanical damage. Activates muscle satellite cells to initiate repair and hypertrophy.